SCYX SCYNEXIS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—
Returns
ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.60M | $3.75M | $140.14M | $5.09M | $13.16M |
| R&D expense | $22.28M | $26.41M | $30.93M | $27.26M | $23.77M |
| SG&A expense | $14.39M | $14.46M | $20.92M | $62.96M | $49.92M |
| Operating income | -$16.07M | -$37.12M | $72.67M | -$85.76M | -$60.84M |
| Interest expense | $173,000 | $828,000 | $3.13M | $5.20M | $2.66M |
| Pretax income | -$8.61M | -$21.14M | $67.18M | -$67.51M | -$35.95M |
| Income tax | $0 | $151,000 | $138,000 | -$4.70M | -$3.09M |
| Net income | -$8.61M | -$21.29M | $67.04M | -$62.81M | -$32.87M |
| EBITDA | — | -$37.12M | $73.25M | -$85.15M | -$60.46M |
| EPS (basic) | -0.17 | -0.44 | 1.40 | -1.47 | -1.25 |
| EPS (diluted) | -0.17 | -0.44 | 1.39 | -1.47 | -1.25 |
| Weighted avg. shares (diluted) | 49.93M | 48.51M | 48.39M | 42.61M | 26.38M |
| Balance sheet | |||||
| Cash & equivalents | $21.26M | $16.59M | $34.59M | $46.03M | $104.70M |
| Short-term investments | $18.77M | $43.25M | $40.31M | $27.69M | $0 |
| Receivables | — | — | $0 | $2.10M | $861,000 |
| Inventory | — | — | $0 | $899,000 | $463,000 |
| Current assets | $40.37M | $72.18M | $102.12M | $79.06M | $109.38M |
| PP&E, net | — | — | — | — | $113,000 |
| Intangibles | — | — | $0 | $408,000 | $1.06M |
| Total assets | $59.03M | $90.64M | $128.41M | $87.81M | $119.84M |
| Current liabilities | $5.73M | $24.10M | $16.30M | $17.62M | $13.62M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | $34.39M |
| Total debt | — | — | — | — | $34.39M |
| Total liabilities | $9.65M | $35.57M | $55.45M | $84.58M | $78.58M |
| Shareholders' equity | $49.38M | $55.08M | $72.96M | $3.23M | $41.26M |
| Net debt | — | — | — | — | -$70.31M |
| Shares outstanding | 5.44M | 37.97M | 37.21M | 32.68M | 28.71M |
| Cash flow statement | |||||
| Operating cash flow | -$5.28M | -$24.01M | $60.16M | -$79.88M | -$54.56M |
| Capital expenditure | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | -$54.56M |
| Investing cash flow | $24.31M | $6.15M | -$34.88M | -$27.39M | -$1.17M |
| Financing cash flow | -$14.17M | -$139,000 | -$36.72M | $48.60M | $67.12M |
| Depreciation & amortization | — | $0 | $580,000 | $606,000 | $379,000 |
| Stock-based compensation | $2.85M | $3.35M | $2.62M | $3.69M | $2.09M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.